GSK Archives - Lupus Research

Tag: GSK

LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA

NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […] Read More

Boston Walk with Us to Cure Lupus

The 2020 Boston Walk with Us to Cure Lupus presented by GSK is the Lupus Research Alliance’s national fundraising program. The Lupus Research Alliance is the largest private sector organization dedicated to advancing lupus research. Walk distance is approximately 5k (3.1 miles) Contact Elizabeth Vega-Eng at lupuswalkboston@lupusresearch.org or at 646-884-6043. Read More

Join ManyOne Can. Walk with Us to Cure Lupus Sept. 12!

July 2, 2020 Saturday, September 12th, 2020 12:00 – 2:00 PM, EDT Register Now ► The Lupus Research Alliance is excited to announce the reimagination of our ManyOne Can. Walk with Us to Cure Lupus presented by GSK. This celebratory Walk experience will unite the entire lupus community as never before – behind one goal, on […] Read More

The Lupus Research Alliance Teams Up with the New York Jets for New Jersey Walk with Us to Cure Lupus 20th Anniversary Event

EAST RUTHERFORD, NEW JERSEY. May 6, 2023. An enthusiastic crowd of nearly 1,500 supporters came together today at MetLife Stadium for the Lupus Research Alliance (LRA) 2023 New Jersey Walk with Us to Cure Lupus to raise nearly $500,000 for lupus research as well as public awareness of the serious and commonly misdiagnosed autoimmune disease. […] Read More

LRA Congratulates GSK on FDA Approval of Benlysta® (belimumab) for Children with Lupus Nephritis

NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved belimumab (Benlysta®) as the first-ever treatment specifically indicated for children aged 5 to 17 with lupus nephritis. Belimumab is already approved by the FDA to treat lupus nephritis in adults […] Read More

2022 New Jersey Walk with Us to Cure Lupus Raises Awareness and Funds for Commonly Misdiagnosed Autoimmune Disease

May 14, 2022 EAST RUTHERFORD, NEW JERSEY. May 14, 2022. The Lupus Research Alliance (LRA) brought together thousands of people to MetLife Stadium for the 2022 New Jersey Walk with Us to Cure Lupus to raise lupus awareness. The MetLife walk marked the 20th anniversary of the LRA’s national Walk Program. As Honorary Chair of […] Read More

The Lupus Research Alliance Unites Global Community at Immersive Virtual Walk Experience to Support Lupus Research

NEW YORK, NY. September 30, 2021. The Lupus Research Alliance (LRA) is pleased to invite the global community to join together as one at its virtual ManyOne Can. Walk with Us to Cure Lupus celebratory event. The aim is to unite and inspire the entire world on one day, Saturday, October 2, 2021, to achieve one […] Read More

Update from LRA’s President on COVID-19 Vaccines in Lupus

January 14, 2020 Dear Friends, Happy New Year! On behalf of all of us at the Lupus Research Alliance (LRA), thank you so much for your kindness and generosity in 2020 and prior years. 2021 starts off with some exciting milestones for the lupus community including a new treatment for lupus nephritis. But Recently, our […] Read More

Independent Panel Gives High Marks to New Lupus Nephritis Therapies, Policies Reflect LRA Feedback

April 20, 2021 At a public meeting in March led by the Institute for Clinical and Economic Review (ICER), an independent panel voted unanimously that both belimumab (Benlysta) and voclosporin (Lupkynis), newly approved to treat lupus nephritis, provide a health benefit over standard therapy alone. ICER’s policy recommendations for the use of these two medications […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More